Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

January 11, 2023

Study Completion Date

February 8, 2023

Conditions
AnemiaMyelodysplastic Syndrome
Interventions
DRUG

FG-4592

Oral

DRUG

Placebo

Oral

Trial Locations (38)

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Anhui Provincial Hospital, Hefei

The First Affiliated Hospital of Anhui Medical University, Hefei

China-Japan Friendship Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Peking University First Hospital, Beijing

Peking University Third Hospital, Beijing

Xiyuan Hospital, CACMS, Beijing

Fujian Medical University Union Hospital, Fuzhou

Lanzhou University Second Hospital, Lanzhou

Guangdong General Hospital, Guangzhou

Nan Fang Hospital, Guangzhou

Zhuzhou Central Hospital, Zhuzhou

Hainan Central Hospital, Haikou

Second hospital of Hebei Medical University, Shijiazhuang

Tumor Hospital of Henan province, Zhengzhou

Tongji Hospital, Tongji Medical College of HUST, Wuhan

Union Hospital Affiliated Tongji Medical College Huazhong University of Science and Technolog, Wuhan

The Third Xiangya Hospital of Central South University, Changsha

Jiangsu Province Hospital, Nanjing

Zhongda Hospital Southeast University, Nanjing

The First Affiliated Hospital Of Soochow University, Suzhou

Northern Jiangsu People's Hospital, Yangzhou

Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan

Qilu Hospital of Shandong University, Jinan

The Affiliated Hospital of Xuzhou Medical University, Jinan

Huashan Hospital Affiliated to Fudan University, Shanghai

Shanghai Sixth People's Hospital, Shanghai

Shanghai Tongji Hospital, Shanghai

Shaanxi Provincial People's Hospital, Xian

The First Affiliated Hospital of Xi'an Jiao Tong University Medical College, Xian

Sichuan Provincial People's Hospital, Chengdu

West China Hospital, Sichuan University, Chengdu

Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin

The Second Hospital of Tianjin Medical University, Tianjin

Tianjin Medical University General Hospital, Tianjin

First Affiliated Hospital of Kunming Medical University, Kunming

The First Affiliated Hospital, Zhejiang University Medical College, Hangzhou

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

FibroGen

INDUSTRY